Archives: News

Sponsorship enables increased awareness of type 1 diabetes and investment in research, building upon Sun Life’s global commitment toward type 1 and type 2 diabetes

 

Toronto, ON – (April 25, 2019) – JDRF Canada is pleased to announce Sun Life Assurance Company of Canada (“Sun Life”) as the title sponsor of its signature Ride event. The newly named Sun Life Ride to Defeat Diabetes for JDRF is a unique stationary cycling event that sees 11,000 Canadians mobilize in communities across the country to pedal and last year alone raised $3.8 million for ground-breaking type 1 diabetes (T1D) research.

JDRF is very proud to be teaming up once again with Sun Life as the title sponsor for this event as they help raise awareness and funds for finding a cure to T1D. Sun Life became presenting sponsor of the Ride in 2017 and title sponsor of JDRF’s signature Walk event in 2018, solidifying their strong commitment to diabetes in Canada as part of their overall purpose of helping clients achieve a lifetime of financial security and live healthier lives. Now, with their increased involvement as title sponsor of the Ride, Sun Life further establishes themselves as proud supporters of the T1D community.

 “We are excited and proud to welcome our longstanding partner, Sun Life, as title sponsor for our Ride,” said Dave Prowten, President & CEO of JDRF Canada. “This partnership will be the second JDRF signature event in which Sun Life acts as a title sponsor, bringing their commitment to diabetes in Canada to the next level. Sun Life’s support through their sponsorship, corporate matching and employee participation will enable us to continue to increase awareness of T1D, accelerate the pace of diabetes research and ultimately work toward our singular vision: a world without T1D.”

The Sun Life Ride to Defeat Diabetes for JDRF has something for everyone – including team building, exercise, fun music, high-energy excitement, and the knowledge that ride participants are contributing to a great cause. This year’s Ride event will be held in over 35 locations across the country.

 “Sun Life is proud to deepen our commitment to JDRF and to those living with type 1 diabetes in Canada as the Title Sponsor of the Sun Life Ride to Defeat Diabetes for JDRF.  We’re teaming up with riders from coast-to-coast as they challenge diabetes and make a difference for Canadians who live with the disease,” said Jacques Goulet, President, Sun Life Canada. “At Sun Life, we are committed to helping raise awareness and funds for the prevention, care and research of both type 1 and type 2 diabetes. Our partnership with JDRF in support of the Ride also helps us deliver on our purpose of helping our clients achieve a lifetime of financial security and to live healthier lives.”

To join  the Sun Life Ride to Defeat Diabetes for JDRF, raise funds for diabetes research, and pedal toward a cure visit jdrfride.ca to learn more and help turn type one into type none.

-30-

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes research. JDRF’s goal is to progressively remove the impact of type 1 diabetes from people’s lives until we achieve a world without this disease. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit www.breakthrought1d.ca.

 

About Sun Life in the community

At Sun Life Financial, we are committed to building sustainable, healthier communities for life and we’re proud to hold the Caring Company designation from Imagine Canada. Community wellness is an important part of our sustainability commitment and we believe that by actively supporting the communities in which we live and work, we can help build a positive environment for our Clients, Employees, advisors and shareholders. Our philanthropic support focuses on two key areas: health, with an emphasis on diabetes awareness, prevention, care and research initiatives through our Team Up Against DiabetesTM platform; and arts and culture, through our award-winning Making the Arts More AccessibleTM program. In Quebec, our sponsorship and donation initiatives also focus on home economics and financial education.

We also partner with sports properties in key markets to further our commitment to healthy and active living. Our Employees and advisors take great pride in volunteering over 18,000 hours each year and contribute to making life brighter for individuals and families across Canada.

 

JDRF Media Contact:	Sun Life Media Contact:
Arielle Nkongmeneck	Yasna Criscione
JDRF Canada	Sun Life Financial
T: (647) 789-2000 ext. 2046	T: (416) 204-8110
ankongmeneck@jdrf.ca	yasna.criscione@sunlife.com

                 
 

 

 

Toronto, ON (March 21, 2019) – JDRF Canada is pleased to announce the appointment of Dr. Sarah Linklater as Chief Scientific Officer (CSO). Sarah has over a decade of extensive experience as a professional scientific editor, with a focus on clinical diabetes and endocrinology, basic immunology and other areas of the life sciences. Prior to working in publishing, Sarah carried out research on mechanisms of immune regulation at UBC in Vancouver and at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. In her role as JDRF Canada’s CSO, Sarah will lead the organization’s efforts to advance and expand its research partnerships and support its efforts to effectively engage the type 1 diabetes (T1D) community. Sarah will start her new role on April 16, 2019.

“I’m really excited for the opportunity to shape T1D research in Canada, and work with a global organization whose mission is to improve the lives of people living with T1D and ultimately cure this disease,” said Sarah.

“We are thrilled to have Sarah join our passionate team of professionals.  She brings a unique combination of scientific experience and communications expertise that will help us accelerate our research program,” said Dave Prowten, President and CEO of JDRF Canada. 

Dr. Sarah E. Linklater (née Allan) completed her PhD in Experimental Medicine at the UBC Faculty of Medicine under the supervision of Professor Megan Levings, a JDRF funded researcher. Her PhD studies focused on the function of regulatory T cells in health and autoimmune disease and she has published several peer-reviewed original research articles, reviews and book chapters on the topic, as well as conducted a number of podium presentations. In her latest role, she helped to launch The Lancet Diabetes & Endocrinology, now the leading clinical diabetes journal worldwide, and became Editor-in-Chief in 2017. Her responsibilities included: maintaining an international network of advisors, authors, and peer reviewers; critically appraising and triaging research, review, and opinion content submitted to the journal; overseeing the peer review processes of the editorial team; and leading a variety of special projects in clinical diabetes and endocrinology. 

-30-

 

About JDRF
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.7 billion to T1D research. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. 

For more information, please visit breakthrought1d.ca.

Media contact:

Soledad Vega
Manager, Marketing and Communications
JDRF Canada
647-459-7881
svega@jdrf.ca

 

 

 

 

 

 

 

 

 

Toronto, ON – March 20, 2019 – JDRF Canada, the leading global funder of type 1 diabetes research, welcomed the news in this year’s federal budget that the government intends to end the practice of clawing back contributions to Registered Disability Savings Plans (RDSPs) for those whose eligibility status for the Disability Tax Credit (DTC) has changed.

“We’re pleased the government has recognized the unfairness that was inherent in clawing back funds, in some cases amounting to tens of thousands of dollars, that vulnerable Canadians used to cover their extraordinary medical expenses, says Dave Prowten, President and CEO at JDRF Canada. Canadians with type 1 diabetes spend up to $15,000 annually in out of pocket costs managing their disease. The move to end the RDSP clawback is welcome; though the government has missed an opportunity in not moving forward with a national diabetes strategy.”

JDRF had made a number of recommendations to the Government of Canada in its pre-budget submission– that Canada develop a national diabetes strategy, fix problems with the Disability Tax Credit and the Registered Disability Savings Plan, introduce a National Diabetes Registry, and include all types of insulin under any National Pharmacare Plan that’s introduced.  

JDRF Canada along with Diabetes Canada and other groups had been urging the government to commit to funding a national diabetes strategy in Budget 2019 before the burden of diabetes gets worse for Canadians, the health care system and the economy.

“Canada is in desperate need of a measurable outcome-focused national strategy,” adds Prowten. “Without a coordinated, national approach to tackling diabetes the incidence rate in Canada will continue to escalate.”

Diabetes prevalence in Canada is not only skyrocketing, but is already among the worst of developed countries. Canada now has the sixth highest incidence rate of type 1 diabetes (T1D) in children age 14 years and younger in the world. With T1D increasing faster in Canada than in many other developed countries (effectively doubling every 20 years), and type 2 diabetes increasing at an even faster rate, there is an urgent need to address what many now refer to as the diabetes epidemic.

For this reason, JDRF Canada made support for a national diabetes strategy one of five key recommendations in our 2019 Pre-Budget Submission. JDRF will continue to advocate for our other recommendations. For example:

• Including insulin amongst the drugs covered by any national pharmacare program that’s developed. Noting the government’s intention to move forward and develop a national pharmacare program, including a new national formulary of prescription drugs, JDRF will continue to express the need for all types of insulin to be covered for all Canadians with T1D.
• Changes to the Income Tax Act aimed at fixing problems that Canadians with T1D encounter in qualifying for the Disability Tax Credit and the Registered Disability Savings Plan. We remain hopeful that these recommendations might still be addressed and look forward to the Disability Advisory Committee’s first report this spring.

Considering the difficulties that Canadians with T1D still encounter in qualifying for the Disability Tax Credit, more consideration should have been given to the simple and practical amendments JDRF had proposed for the Income Tax Act and Canada Disability Savings Regulations.

We will continue to strongly advocate that Canada develop a national diabetes strategy, a type 1 diabetes registry of patients and for all other recommendations from JDRF’s pre-budget submission not included in today’s budget.

-30-

About JDRF

JDRF is the leading global organization funding type 1 diabetes research. Our goal is to raise funds to support the most advanced international type one diabetes research and progressively remove the impact of this disease from people’s lives – until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit breakthrought1d.ca.         

 

Media contact
Arielle Nkongmeneck
Bilingual Marketing and Communications Specialist
JDRF Canada
647-789-2025
ankongmeneck@jdrf.ca

 

 

Toronto, ON, March 4, 2019 – Two  pioneering Canadian investigators pursuing careers in type 1 diabetes research have each been awarded a post-doctoral fellowship ($60,000 CAD), thanks to a longstanding partnership between Eli Lilly Canada Inc. (Lilly Canada) and JDRF Canada.

The program that disburses these fellowships, which is called the JDRF Canadian Clinical Trial Network (CCTN) Eli Lilly Post-doctoral Fellowship in Clinical Translation in Type 1 Diabetes, is a generous and vital investment in the area of type 1 diabetes research.  It provides incentive for young investigators to further their medical studies and establish themselves as future leaders in the field.

“The JDRF and Lilly Canada Fellowship Program is an important investment in our next generation of scientists and researchers who continue to advance our understanding of diabetes,” says Dr. Joanne Lorraine, Diabetes medical director at Lilly Canada. “Today’s post-doctoral fellows have the opportunity to positively change the landscape for Canadians living with this disease, and to bring us one step closer to a world without type 1 diabetes.”

The 2018 recipients of the postdoctoral fellowship grants are:

Investigator: Kirsten Ward-Hartstonge, MD, University of British Columbia

Project: Harmonized biomarkers to measure response to ustekinumab in type 1 diabetes 

In type 1 diabetes, cells from the immune system called T-cells attack and destroy insulin-producing beta cells, leaving affected individuals with a lifelong dependence on insulin. Even with insulin injections, blood glucose control is imperfect, leading to an increased risk of complications, including chronic hyperglycemia and a shortened life span. Preliminary work demonstrated that a biological drug, known as ustekinumab, can be safely administered to young adults with new onset diabetes. Results from this pilot study also indicated that changes in immune cells may predict clinical responses to ustekinumab.

Two multi-centre clinical trials in the UK and Canada have recently been planned to test the ability of ustekinumab to halt the progression of type 1 diabetes in children or young adults with recent onset type 1 diabetes (i.e. within 100 days of diagnosis). The UK trial includes 72 children aged 12 to 18, and the Canadian trial includes 66 young adults aged 18 to 25. These larger trials will be harmonized to allow results to be compared across both trials. In order to harmonize both studies, Dr. Hartstonge and her collaborators will standardize assays and laboratory protocols at both trial locations.  Blood samples will be taken from participants before and at multiple time points post-therapy. Sample collection time, processing and storage conditions will be standardized and cross-lab training will be performed. The harmonization of these independent trials will increase statistical power to more rapidly determine whether or not ustekinumab is an effective treatment and if immune cells can act as biomarkers to predict a response to treatment.

Investigator: Rangarajan Sambathkumar, PhD, University Health Network (TO)

Project: Genome engineering approaches to improve the functional maturation of insulin-producing beta cells from human pluripotent stem cells 

Dr. Sambathkumar and his team are focusing on improving beta cell maturation from human embryonic stem cells (hESC) for the development of a cell-based therapy for type 1 diabetes.

Human pluripotent stem cells (hPSC) may offer an option to large scale replacement therapy, since they have the ability to divide indefinitely. In recent years, much progress has been made in the generation of insulin-producing beta-like cells from various hPSC lines. These cell lines are not fully mature, and resemble fetal beta cells more than they do adult beta cells. The goal of this project is to improve functional beta cell maturation in vitro using genetic engineering approaches. With the creation of a more functional beta cell for transplantation, this research may contribute to beta cell regeneration therapies that could cure type 1 diabetes.

About JDRF Canada:

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our goal is to raise funds to support the most advanced international T1D research and progressively remove the impact of this disease from people’s lives – until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. JDRF is the largest charitable supporter of T1D research. For more information, please visit breakthrought1d.ca.

About Eli Lilly Canada (Lilly Canada): 

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people’s needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism.

Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world’s first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at www.lilly.ca.

For more information:

Soledad Vega
National Marketing and Communications Manager
JDRF Canada
Phone: 647-459-7881 
Email: svega@jdrf.ca  

 

 

 

Approval of Canada’s first Hybrid Closed-Loop System will help Canadians with type 1 diabetes keep their blood sugar levels in an optimal range for a greater amount of time

Toronto, Ont. — October 10, 2018 – JDRF Canada, the leading global funder of type 1 diabetes research, applauds Health Canada’s recent license of the Medtronic MiniMed^TM 670G hybrid closed-loop insulin delivery system – the first self-adjusting insulin pump to be licensed in Canada.

This is an exciting day for the 300,000 Canadians living with type 1 diabetes because this device will help keep their blood sugar levels in a target range for longer and avoid the dangers of both low and high blood sugar throughout the day and overnight.

“JDRF has actively supported research into the development of closed-loop insulin delivery systems for many years and this is a major milestone in improving the lives of Canadians with type 1 diabetes. This device will help people with type 1 keep their blood sugar in target range for longer, so they can live easier, longer and healthier lives – and that’s exactly what JDRF is striving to achieve as we work towards a cure,” says Dave Prowten, President and CEO, JDRF Canada.

Because people with type 1 diabetes are not able to produce insulin, they need to check their blood glucose levels several times a day and then calculate and inject an appropriate insulin dosage. The MiniMed^TM 670G system can actually replicate some of the functions of the pancreas by automating basal insulin delivery. This device consists of an insulin pump, continuous glucose monitor and smart software to automate the delivery of the right amount of insulin every 5 minutes. It is called a hybrid closed-loop system because the patient still has to enter carbohydrates when they are eating to make decisions about meal-time insulin.

People living with type 1 diabetes live in constant fear of hypoglycemia, low blood sugar levels that if left unchecked can be life-threatening. The MiniMed^TM 670G system will reduce the worry of these dangerous lows that can happen overnight and allow people with type 1 (and their caregivers) to sleep better without having to get up multiple times through the night to check blood sugar or give insulin.

“JDRF Canada maintains an open dialogue with Health Canada, device manufacturers and policy makers so we can ensure that Canadians have access to these kinds of life-changing technologies within a reasonable time frame. We will continue to advocate to get critical developments like these into their hands,” says Patrick Tohill, Director of Government Relations, JDRF Canada. 

For more information about the Medtronic MiniMed^TM 670G system please visit: www.medtronic.ca

About Type 1 Diabetes

• Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. It is a life-threatening chronic condition requiring continuous and life-long management
• The onset is not related to diet or lifestyle. There is nothing anyone can do to prevent it and, at present there is no cure. It can affect both children and adults and lasts a lifetime.
• People with type 1 diabetes need to test their blood sugar and give themselves insulin through injections or a pump multiple times per day – every day for the rest of their lives.
• Insulin is not a cure for type 1 diabetes, nor does it prevent complications which may include kidney failure, blindness, heart disease, stroke and pregnancy complications.
• T1D can be difficult to live with. While trying to balance insulin doses with food intake and daily activities, people living with T1D must always be prepared for serious hypoglycemic (low blood sugar) and hyperglycemic (high blood sugar) reactions, both of which can be life-threatening.

About JDRF

JDRF is the leading global organization funding type 1 diabetes research. Our goal is to raise funds to support the most advanced international type one diabetes research and progressively remove the impact of this disease from people’s lives – until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit breakthrought1d.ca.         

Media contact
Soledad Vega
Manager, Marketing and Communications
JDRF Canada
647-459-7881
svega@jdrf.ca

Sponsorship supports growth of type 1 diabetes research and awareness, building upon Sun Life Financial’s $22 million global investment to date 

 

TORONTO, ON – (May 3, 2018) — JDRF Canada is pleased to announce Sun Life Assurance Company of Canada (“Sun Life”) as the title sponsor of its longstanding signature Walk event. The newly titled Sun Life Walk to Cure Diabetes for JDRF is the largest diabetes fundraising event in Canada which aims to drive fundraising efforts to help accelerate the pace of research and inspire Canadians to learn more about type 1 diabetes.

This partnership will continue to solidify Sun Life’s already strong commitment to diabetes in Canada as part of its overall strategy of helping build healthy, sustainable communities for life. As part of the title sponsorship, Jacques Goulet, President of Sun Life Financial Canada has been named the Honorary Chair of the Sun Life Walk to Cure Diabetes for JDRF.

“We’re proud to be named the title sponsor of JDRF’s signature walk event as we deepen our commitment to diabetes awareness, prevention, care and research,” said Jacques Goulet, President, Sun Life Financial Canada. “This new sponsorship is a natural extension of our long history of diabetes support and our existing partnership with JDRF. I’m particularly honoured to take on the role of Honorary Chair and rally our employees, advisors, Clients and Canadians to take part in the Walk and the fight against type 1 diabetes.”

Sun Life Financial is currently the presenting sponsor of the JDRF Revolution Ride to Defeat Diabetes and has been the national sponsor of the JDRF Walk since 2016.

“We are thrilled to welcome Sun Life Financial as the title sponsor of the Walk. We are aligned on our commitment to bringing greater awareness to type 1 diabetes and accelerating the pace of type 1 diabetes research,” said Dave Prowten, President & CEO of JDRF Canada.

This year’s Walk event will be held in over 65 cities across the country and will include a virtual Walk led by JDRF’s National Spokesperson, NHL hockey star, Max Domi. In celebration of the  25th anniversary of the Walk, Sun Life Financial will match any online donation of $25 or more between May 3 – 18, up to a maximum of $125,000. For a complete list of locations and dates, visit jdrfwalk.ca.

Sun Life Financial is focused on helping people achieve lifetime financial security and live healthier lives, taking a holistic approach to supporting the well-being of our Clients, employees and communities with the end goal of helping to achieve physical, mental and financial resiliency both now and in the future. Sun Life Financial has proudly committed more than $22 million in support of diabetes awareness, prevention, care and research initiatives since announcing support of the cause in 2012.

Sun Life employees and advisors across the country will also team up with JDRF to drive fundraising efforts and raise much-needed research dollars. Goulet adds, “Sun Life employees and advisors have continually embraced diabetes as our global cause, showing their overwhelming support for local diabetes initiatives like the Walk. We look forward to connecting with employees and advisors across the country to help make the Walk a success.”

 

About Sun Life Financial in the community

At Sun Life Financial, we are committed to building sustainable, healthier communities for life and we’re proud to hold the Caring Company designation from Imagine Canada. Community wellness is an important part of our sustainability commitment and we believe that by actively supporting the communities in which we live and work, we can help build a positive environment for our Clients, employees, advisors and shareholders. Our philanthropic support focuses on two key areas: health, with an emphasis on diabetes awareness, prevention, care and research initiatives through our Team Up Against Diabetes™ platform; and arts and culture, through our award-winning Making the Arts More Accessible™ program. We also partner with sports properties in key markets to further our commitment to healthy and active living. Our employees and advisors take great pride in volunteering over 29,000 hours each year and contribute to making life brighter for individuals and families across Canada. Read more about Sun Life Financial in the community.

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes research. JDRF’s goal is to progressively remove the impact of type 1 diabetes from people’s lives until we achieve a world without this disease. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit www.breakthrought1d.ca.   

Note to Editors: All figures in Canadian dollars except as otherwise noted.

-30-

Media Relations Contact:

Tara Peever McClean

Manager, Corporate Communications

T: 416-420-4707

tara.peever.mcclean@sunlife.com

 

Erin Whittaker

National Bilingual Communications Specialist

JDRF Canada

T: 647-459-7833

ewhittaker@jdrf.ca

 

Toronto, ON, May 3, 2018 – Sonia Sidhu, Member of Parliament for Brampton South, and Chair of the All-Party Caucus on Diabetes, on behalf of the Honourable Ginette Petitpas Taylor, Minister of Health, highlighted an investment of $7.7M in type 1 diabetes research.

This funding will support the clinical trials of ground-breaking therapies in order to accelerate the development of new treatments for people living with type 1 diabetes.

There are more than 300,000 Canadians living with type 1 diabetes. People with type 1 diabetes must inject themselves with insulin several times per day to keep their blood glucose levels normal, and despite their best efforts, they can sometimes experience serious complications. There is no cure.

“JDRF is focused on launching and sustaining innovative research and clinical trials that will result in new treatments to improve the health and quality of life of the over 300,000 Canadians affected by this disease,” says Dave Prowten, President and CEO of JDRF Canada. “By supporting talented scientists in the field, we are working together and laying the foundation for a future without type 1 diabetes.” 

The three projects are:

• Dr. Rémi Rabasa-Lhoret, from the Institut de recherches cliniques de Montréal, will study how Quebec teens and adults can improve control of their blood glucose levels by participating in an online educational program. He will also create a patient registry to evaluate the effectiveness of wearable devices for preventing complications from dangerously low blood sugar.  
• Dr. Farid Mahmud, from The Hospital for Sick Children in Toronto, will test whether a new drug helps teens with type 1 diabetes by improving control of blood glucose levels in the interest of preventing long-term kidney and heart issues.
• Dr. Gillian Booth, from St. Michael’s Hospital in Toronto, will pilot a new way of treating people with type 1 diabetes through frequent, brief virtual visits with doctors via videoconferencing on computers, tablets, and smartphones.

These projects are a joint investment under JDRF and the Canadian Institutes of Health Research’s (CIHR) Partnership to Defeat Diabetes announced in April 2017. CIHR funding was provided through the Innovation Clinical Trials initiative of Canada’s Strategy for Patient-Oriented Research.

***

At the Canadian Institutes of Health Research (CIHR) we know that research has the power to change lives. As Canada’s health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.

JDRF is the leading global organization funding type 1 diabetes research. JDRF’s goal is to progressively remove the impact of type 1 diabetes from people’s lives until we achieve a world without this disease. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable supporter of type 1 diabetes research. For more information, please visit www.breakthrought1d.ca.

 

Contacts
Erin Whittaker
National Bilingual Communications Specialist, JDRF Canada
647-459-7833
ewhittaker@jdrf.ca

 

Media Relations
Canadian Institutes of Health Research
613-941-4563
mediarelations@cihr-irsc.gc.ca